- CITATIONS: 2
|Application ||WB, IHC-P, IF, E|
|Calculated MW||42344 Da|
|Antigen Region||342-371 aa|
|Other Names||Serine/threonine-protein kinase 17B, DAP kinase-related apoptosis-inducing protein kinase 2, STK17B, DRAK2|
|Target/Specificity||This DRAK2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 342-371 amino acids from the C-terminal region of human DRAK2.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||DRAK2 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Phosphorylates myosin light chains (By similarity). Acts as a positive regulator of apoptosis.|
|Cellular Location||Nucleus. Cell membrane. Endoplasmic reticulum-Golgi intermediate compartment. Note=Colocalizes with STK17B at the plasma membrane.|
|Tissue Location||Highly expressed in placenta, lung, pancreas. Lower levels in heart, brain, liver, skeletal muscle and kidney|
Provided below are standard protocols that you may find useful for product applications.
DRAK2 is a novel serine/threonine kinase that induces apoptosis via catalytic activity. DRAKs present high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases. DRAK2 is located in nucleus, and the messenger RNA is ubiquitously expressed in human tissues.
Sanjo, H., et al., J. Biol. Chem. 273(44):29066-29071 (1998).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.